Literature DB >> 16604100

A role for fMRI in optimizing CNS drug development.

David Borsook1, Lino Becerra, Richard Hargreaves.   

Abstract

Drug development today needs to balance agility, speed and risk in defining the probability of success for molecules, mechanisms and therapeutic concepts. New techniques in functional magnetic resonance imaging (fMRI) promise to be part of a sequence that could transform drug development for disorders of the central nervous system (CNS) by examining brain systems and their functional activation dynamically. The brain is complex and multiple transmitters and intersecting brain circuits are implicated in many CNS disorders. CNS therapeutics are designed against specific CNS targets, many of which are unprecedented. The challenge is to reveal the functional consequences of these interactions to assess therapeutic potential. fMRI can help optimize CNS drug discovery by providing a key metric that can increase confidence in early decision-making, thereby improving success rates and reducing risk, development times and costs of drug development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16604100     DOI: 10.1038/nrd2027

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  62 in total

1.  The cognitive-emotional brain: Opportunities [corrected] and challenges for understanding neuropsychiatric disorders.

Authors:  Alexander J Shackman; Andrew S Fox; David A Seminowicz
Journal:  Behav Brain Sci       Date:  2015       Impact factor: 12.579

2.  Neural substrates of abstinence-induced cigarette cravings in chronic smokers.

Authors:  Ze Wang; Myles Faith; Freda Patterson; Kathy Tang; Kia Kerrin; E Paul Wileyto; John A Detre; Caryn Lerman
Journal:  J Neurosci       Date:  2007-12-19       Impact factor: 6.167

Review 3.  Neuroimaging, genetics and the treatment of nicotine addiction.

Authors:  Riju Ray; James Loughead; Ze Wang; John Detre; Edward Yang; Ruben Gur; Caryn Lerman
Journal:  Behav Brain Res       Date:  2008-06-05       Impact factor: 3.332

4.  Evaluation and comparison of GLM- and CVA-based fMRI processing pipelines with Java-based fMRI processing pipeline evaluation system.

Authors:  Jing Zhang; Lichen Liang; Jon R Anderson; Lael Gatewood; David A Rottenberg; Stephen C Strother
Journal:  Neuroimage       Date:  2008-04-03       Impact factor: 6.556

5.  Neuroimaging as a tool for pain diagnosis and analgesic development.

Authors:  Karolina Wartolowska; Irene Tracey
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

6.  Neuroanatomical targets of reboxetine and bupropion as revealed by pharmacological magnetic resonance imaging.

Authors:  Sakthivel Sekar; J Van Audekerke; G Vanhoutte; A S Lowe; A M Blamire; A Van der Linden; T Steckler; M Shoaib; Marleen Verhoye
Journal:  Psychopharmacology (Berl)       Date:  2011-05-07       Impact factor: 4.530

Review 7.  The role of machine learning in neuroimaging for drug discovery and development.

Authors:  Orla M Doyle; Mitul A Mehta; Michael J Brammer
Journal:  Psychopharmacology (Berl)       Date:  2015-05-28       Impact factor: 4.530

Review 8.  Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET).

Authors:  Shil Patel; Karl Schmidt; Jacob Hesterman; Jack Hoppin
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

Review 9.  Towards a theory of chronic pain.

Authors:  A Vania Apkarian; Marwan N Baliki; Paul Y Geha
Journal:  Prog Neurobiol       Date:  2008-10-05       Impact factor: 11.685

Review 10.  A key role of the basal ganglia in pain and analgesia--insights gained through human functional imaging.

Authors:  David Borsook; Jaymin Upadhyay; Eric H Chudler; Lino Becerra
Journal:  Mol Pain       Date:  2010-05-13       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.